Synthetic biotechnology company Amyris Inc. has filed for a Chapter 11 bankruptcy and plans to sell its consumer brands and focus on developing its sustainable ingredients business.
In Bankruptcy, Amyris To Sell Consumer Brands, Turn Focus To Smaller Ingredients Business
Synthetic biotech company Amyris files for Chapter 11 bankruptcy for its multiple US corporate entities and plans to sell its consumer brands.
More from Ingredients & Safety
• By
Reclassifying ethanol as a carcinogenic, mutagenic, or reprotoxic substance - something the European Chemicals Agency seems likely to do in the near future - would be “tantamount to a de facto ban” with “fatal consequences” for medical care in Germany, says Pharma Deutschland in a joint paper with 13 other German healthcare industry associations.
• By
Two AESGP papers reviewing the evidence for AMR risk associated with a range of OTC antifungals and antivirals conclude there is litte to no risk associated with the responsible self-care use of such medicines.
• By
“Protecting the environment is a shared responsibility. It is unfair to expect only two sectors to fund wastewater treatment modernization and operation,” argues AESGP director general Jurate Švarcaite.
• By
Supplements already under close scrutiny in the EU have been linked to severe adverse effects on the musculoskeletal system and liver, even at low doses.
More from HBW Insight
• By
Swiss firm reports highest revenues in its history as restructure pays off for its pharma and cosmetics businesses in 2024.
• By
Industry lobbing for pharmaceuticals to be exempt from President Trump’s sweeping US tariffs appears to have paid off.
• By
The departure data emerged along with a Health and Human Services Department memo describing conceptual plans to consolidate and restructure offices at the FDA and other agencies.